Amyloid β inhibitor
/ Wren Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 16, 2023
The Potential of Blood Tests to Improve Screening and Monitoring in Alzheimer Disease Clinical Trials: Ronald C. Petersen, MD, PhD
(NeurologyLive)
- "These trials are enormously expensive. If we have to PET scan thousands of people to find out who's eligible, that's not practical, it's not affordable. But the plasma markers are giving us an index that we could do a blood test. If the person is positive on the blood test, then move them forward to PET imaging or cerebrospinal fluid analysis."
Video
1 to 1
Of
1
Go to page
1